Basic Information
SIRION Biotech GmbH aims to advance a new generation of viral vector technologies for gene and cell therapy as well as vaccine development. SIRION develops novel therapeutic viral vectors and utilizes proprietary technology platforms based on lentivirus, adenovirus, and adeno-associated virus to accelerate its partners' progress in drug development.
SIRION Biotech GmbH
Germany
15~50 people
January 01, 2005
info@sirion-biotech.de
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios